Inactive Instrument
ExpreS2ion Biotech Holding AB Stock Nasdaq Stockholm
Stocks
SE0008348262
Pharmaceuticals
| Market Cap | 28.62M 2.9M 2.54M 2.38M 2.18M 4.08M 278M 4.08M 11.04M 142M 10.9M 10.66M 457M | P/E 2026 * |
-
| P/E 2027 * | - |
|---|---|---|---|---|---|
| Enterprise Value | 28.62M 2.9M 2.54M 2.38M 2.18M 4.08M 278M 4.08M 11.04M 142M 10.9M 10.66M 457M | EV / Sales 2026 * |
0.94x | EV / Sales 2027 * | - |
| Free-Float |
99.89% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: ExpreS2ion Biotech Holding AB
| 1 day | +2.34% |
| Manager | Title | Age | Since |
|---|---|---|---|
Bent Frandsen
CEO | Chief Executive Officer | - | 2019-12-19 |
Keith Alexander
DFI | Director of Finance/CFO | 50 | 2020-09-30 |
Max M. Søgaard
CTO | Chief Tech/Sci/R&D Officer | - | 2019-12-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Martin Jensen
CHM | Chairman | 66 | 2009-12-31 |
Jakob Knudsen
BRD | Director/Board Member | 58 | 2017-03-31 |
Karin Garre
BRD | Director/Board Member | 69 | 2021-05-25 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +2.34% | -2.28% | - | - | 2.9M | ||
| +0.72% | +3.85% | +34.96% | -2.54% | 80.27B | ||
| +5.56% | +26.98% | +587.35% | +82.58% | 72.88B | ||
| -0.62% | +2.87% | -10.26% | -29.08% | 61.51B | ||
| -0.78% | -1.49% | -11.82% | +28.69% | 47.39B | ||
| +0.66% | +1.72% | +3.39% | +159.99% | 46.58B | ||
| +2.87% | +4.25% | +60.22% | -12.54% | 33.3B | ||
| +1.83% | +4.26% | +49.81% | +118.47% | 25.73B | ||
| +0.97% | +10.52% | +11.29% | +166.67% | 22.88B | ||
| +1.04% | +1.96% | +59.16% | +103.91% | 15.82B | ||
| Average | +0.94% | +6.00% | +87.12% | +68.46% | 45.15B | |
| Weighted average by Cap. | +0.55% | +7.38% | +120.73% | +51.49% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 30.4M 3.08M 2.7M 2.53M 2.31M 4.34M 295M 4.34M 11.73M 151M 11.58M 11.33M 485M | - |
| Net income | - | - |
| Net Debt | - | - |
Employees
-
Sector
Pharmaceuticals
Calendar
















